v3.23.3
Subsequent Event - Additional Information (Details) - Subsequent Event - Gilead Sciences, Inc.
Oct. 15, 2023
USD ($)
Timepoint
Program
Director
$ / shares
shares
Option, License and Collaboration Agreement  
Subsequent Event [Line Items]  
Collaboration term 12 years
Proceeds received in collaboration agreement $ 100,000,000
Upfront cash payment received $ 84,800,000
Number of timepoints of program | Timepoint 2
Percentage cover of research and development costs 40.00%
Percentage share of profits and operating loss for products 40.00%
Number of fellow-contributed programs | Program 2
Option, License and Collaboration Agreement | Minimum  
Subsequent Event [Line Items]  
Threshold payment of opt-in fee $ 45,000,000
Option, License and Collaboration Agreement | Maximum  
Subsequent Event [Line Items]  
Threshold payment of opt-in fee 125,000,000
Option, License and Collaboration Agreement | Regulatory and Commercial Milestones | Maximum  
Subsequent Event [Line Items]  
Potential milestone payments 330,000,000
Gilead Equity Agreements | Common Stock  
Subsequent Event [Line Items]  
Upfront equity investment $ 15,200,000
Number of shares sold | shares 13,073,668
Sale of stock, price per share | $ / shares $ 1.16
Expected equity financing completion date Jul. 15, 2024
Percentage of then-outstanding voting capital stock subject to stockholder approval 29.90%
Purchase price per share of additional shares description The purchase price per share for additional shares purchased by Gilead will be equal to the lesser of a 35% premium to the 30-day volume weighted average price immediately prior to the date of purchase or a 35% premium to the 30-day volume weighted average price immediately prior to delivery by Gilead of notice of the anticipated closing date.
Number of days volume considered for weighted average price to calculate premium 30 days
Number of years of standstill and lockup provisions 3 years
Number of directors, right to designate in company board | Director 2
Gilead Equity Agreements | Common Stock | Minimum  
Subsequent Event [Line Items]  
Potential proceeds from equity financing $ 30,000,000
Gilead Equity Agreements | Common Stock | Maximum  
Subsequent Event [Line Items]  
Percentage of premium to weighted average price immediately prior to date of purchase 35.00%
Percentage of premium to weighted average price immediately prior to delivery of notice of closing date 35.00%
Third Year of Collaboration Agreement  
Subsequent Event [Line Items]  
Potential proceeds from collaboration extension fees $ 75,000,000
Fifth Year of Collaboration Agreement  
Subsequent Event [Line Items]  
Potential proceeds from collaboration extension fees 75,000,000
Seventh Year of Collaboration Agreement  
Subsequent Event [Line Items]  
Potential proceeds from collaboration extension fees $ 75,000,000